In contrast, the treatment with serum containing RSBFL could upregulate CAV-1 in AD hippocampal neurons (P < 0.05) with improved p-GSK-3βSer9 and reduced p-GSK-3βTyr216 (P < 0.01), as well as suppressed abnormal phosphorylation of Tau protein. This evidence concerns the gene MAPT and Alzheimer disease.